Alerdez (dezloratadin) syrup 0.5 mg/ml. 50 ml. vial

Antihistamines for systemic use. ATX code R06A X27.

Desloratadine is a selective blocker of peripheral H1 receptors, does not have a sedative effect. Desloratadine is the primary active metabolite of loratadine.

After administration, desloratadine selectively blocks peripheral H1-histamine receptors, since the drug almost does not penetrate the blood-brain barrier. Numerous studies have shown that, in addition to the antihistamine action, desloratadine has anti-allergic and anti-inflammatory effects. It has been established that desloratadine suppresses a cascade of various reactions that underlie the development of allergic inflammation, namely:

• release of pro-inflammatory cytokines, including IL-4, IL-6, IL-8, IL-13;
• release of pro-inflammatory chemokines such as RANTES;
• production of superoxide anion by activated polymorphonuclear neutrophils;
• adhesion and chemotaxis of eosinophils;
• expression of adhesion molecules such as P-selectin;
• IgE-dependent release of histamine, prostaglandin D2 and leukotriene C4;
• acute allergic bronchospasm and allergic cough in animal studies.

The safety of desloratadine in children has been demonstrated in three clinical trials. The drug was used in children aged 6 months to 11 years who needed antihistamine therapy, at a daily dose of 1 mg (age group from 6 to 11 months), 1.25 mg (age group from 1 to 5 years) or 2, 5 mg (6 to 11 years).

The treatment was well tolerated, which was confirmed by the results of clinical laboratory studies, the state of vital signs of the body and ECG data (including the length of the QT interval).

During clinical studies, daily use of the drug desloratadine at a dose of up to 20 mg for 14 days was not accompanied by statistically significant clinical changes in the cardiovascular system. In a clinical pharmacological study, the use of desloratadine 45 mg/day (9 times the therapeutic dose) for 10 days did not cause a prolongation of the QT interval.

Desloratadine almost does not penetrate the blood-brain barrier. When using the recommended dose of 5 mg, the incidence of drowsiness did not exceed that in the placebo group. In clinical studies, desloratadine did not affect psychomotor function at doses up to 7.5 mg.

In addition to the accepted division of allergic rhinitis into seasonal and year-round, according to the duration of symptoms, allergic rhinitis can alternatively be classified into intermittent and persistent.

Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or less than 4 weeks. In the case of persistent allergic rhinitis, symptoms occur for 4 days or more per week or for a period longer than 4 weeks.

The clinical efficacy of desloratadine in the treatment of seasonal allergic rhinitis has been demonstrated in four placebo-controlled multiple dose clinical trials.

In patients with allergic rhinitis, desloratadine effectively eliminated symptoms such as sneezing, nasal discharge and itching, as well as eye irritation, tearing and redness, and itching of the palate.

To relieve symptoms associated with:

• Allergic rhinitis, such as sneezing, nasal discharge, itching, swelling and nasal congestion, as well as itching and redness of the eyes, watery eyes, itchy palate and coughing;
• Urticaria such as itching and rashes.

Hypersensitivity to desloratadine, to any auxiliary component of the drug or to loratadine.

Alerdez (desloratadine) syrup is taken orally, regardless of the meal.

Children:

• 6-11 months:  2 ml syrup (1 mg desloratadine) 1 time per day
• 1-5 years:  2.5 ml syrup (1.25 mg desloratadine) 1 time per day
• 6-11 years:  5 ml of syrup (2.5 mg of desloratadine) 1 time per day.

Adults and adolescents over 12 years of age:  10 ml syrup (5 mg desloratadine) once a day.

To correctly measure the dose of Alerdez (desloratadine) syrup, you should use the dosing device enclosed in the pack (dosing pipette, which has measured divisions from 0.5 to 2.5 ml).

The duration of treatment depends on the severity of the disease.

Therapy for intermittent allergic rhinitis (presence of symptoms less than 4 days per week or less than 4 weeks) should be carried out taking into account the data of the anamnesis: stop after the disappearance of symptoms and restore after their reappearance.

With persistent allergic rhinitis (presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment during the entire period of contact with the allergen.